{"id":"an2690-topical-solution-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus at application site"}]},"_chembl":{"chemblId":"CHEMBL2108694","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by blocking squalene epoxidase, a key enzyme in the synthesis of ergosterol, which is essential for fungal cell membrane integrity. This leads to accumulation of toxic sterol precursors and fungal cell death. It is designed for topical application to treat fungal nail infections (onychomycosis).","oneSentence":"AN2690 is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:31.514Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onychomycosis (fungal nail infection)"}]},"trialDetails":[{"nctId":"NCT01302119","phase":"PHASE3","title":"Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Onychomycosis of Toenails","enrollment":604},{"nctId":"NCT01270971","phase":"PHASE3","title":"Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12-01","conditions":"Onychomycosis of Toenails","enrollment":594},{"nctId":"NCT03405818","phase":"PHASE4","title":"An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-10-22","conditions":"Onychomycosis, Tinea Unguium","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AN2690 Topical Solution, 5%","genericName":"AN2690 Topical Solution, 5%","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2690 is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Onychomycosis (fungal nail infection).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}